CPT code 0590U designates the BIOTIA ID™ Urine NGS Assay, a proprietary molecular diagnostic that sequences microbial DNA from urine to identify 44 potential uropathogens, reporting each as present or absent. As a PLA code, 0590U applies only to a single manufacturer's test and signals the growing use of targeted next-generation sequencing (NGS) panels in infectious disease diagnostics. Nationally, proprietary NGS-based urine testing is significant for guiding antimicrobial stewardship, improving pathogen detection in complicated urinary infections, and informing clinical decision-making where traditional culture may be limited.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code represents, the clinical context for urine NGS testing, typical sites of service, and how PLA designation affects coding specificity. The publication outlines expected benchmarking topics such as coverage patterns, utilization drivers, and reimbursement considerations for proprietary laboratory tests, as well as policy updates affecting PLA codes and implications for laboratory and clinician billing workflows. The content is designed for a national audience of lab billing professionals, clinicians ordering molecular diagnostics, and payer policy analysts.